Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. These presentations will describe the discovery of Arvinas’ two clinical-stage PROTAC degraders, ARV-110 and ARV-471, including the first disclosures of their structures.
Details for the presentations are as follows:
Title: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer
Title: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC® for the treatment of patients with breast cancer
Abstracts will be available for registered attendees on the AACR website beginning on April 9, 2021.
Contacts for Arvinas
Creating Next-Gen Collaborative Post-Pandemic Work Environments
Part I: Let the Geek Speak - via Video!